Table 4. Multivariate Cox proportional analysis for determining disease outcome based on the risk of death related to pathological and molecular variables, adjusted by age and tumor grade.
| Total Sample | Progression | Overall survival | |||
|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | ||
| EPB41L3 meth | No | Ref. | Ref. | ||
| Yes | 1.45 (0.86, 2.46) | 0.175 | 1.79 (1.05, 3.05) | 0.035 | |
| RASSF2 meth | No | Ref. | Ref. | ||
| Yes | 1.21(0.41, 3.55) | 0.735 | 2.16 (0.91, 5.10) | 0.102 | |
| TSP-1 meth | No | Ref. | Ref. | ||
| Yes | 0.78 (0.49, 1.25) | 0.304 | 0.80 (0.49, 1.31) | 0.381 | |
| Astrocytic tumors (n = 103) | |||||
| EPB41L3 meth | No | Ref. | Ref. | ||
| Yes | 1.33 (0.72, 2.45) | 0.371 | 1.88 (1.01, 3.49) | 0.046 | |
| RASSF2 meth | No | Ref. | Ref. | ||
| Yes | 1.07 (0.25, 4.61) | 0.266 | 1.95 (0.65, 5.89) | 0.268 | |
| TSP-1 meth | No | Ref. | Ref. | ||
| Yes | 0.94 (0.55, 1.60) | 0.825 | 1.09 (0.63, 1.91) | 0.751 | |
| Oligodendroglial tumors (n = 29) | |||||
| EPB41L3 meth | No | Ref. | Ref. | ||
| Yes | 2.20 (0.64, 7.58) | 0.209 | 1.21 (0.42, 3.47) | 0.720 | |
| RASSF2 meth | No | Ref. | Ref. | ||
| Yes | 1.88 (0.32, 11.22) | 0.500 | 3.40 (0.69, 16.8) | 0.149 | |
| TSP-1 meth | No | Ref. | Ref. | ||
| Yes | 0.20 (0.04, 1.09) | 0.056 | 0.11 (0.02, 0.58) | 0.003 | |
CI, confidence interval; HR: hazard ratio; meth, methylation; Ref., reference value